ANALISIS EFEKTIFTAS BIAYA TERAPI ANTIKOAGULAN UNTUK PROFLAKSIS TROMBOSIS VENA PASCA TOTAL HIP AND KNEE REPLACEMENT

Niken Luthfiyanti; Kharisma Jayak Pratama; Ayu Dwi  Safitri; Noviana

doi:10.36387/jiis.v10i1.2348

Authors

Niken Luthfiyanti Fakultas Farmasi, Universitas Duta Bangsa, Surakarta, Jawa Tengah, Indonesia
Kharisma Jayak Pratama Fakultas Farmasi, Universitas Duta Bangsa, Surakarta, Jawa Tengah, Indonesia
Ayu Dwi Safitri Fakultas Farmasi, Universitas Duta Bangsa, Surakarta, Jawa Tengah, Indonesia
Noviana Fakultas Farmasi, Universitas Duta Bangsa, Surakarta, Jawa Tengah, Indonesia

DOI:

https://doi.org/10.36387/jiis.v10i1.2348

Keywords:

CEA, Deep Vein Thromboembolism , LMWH, Rivaroxaban, Total Hip and Knee Replacement

Abstract

Orthopedic surgery such as surgery on the hip and knee have a high risk of experiencing Deep Vein Tromoembolism (DVT), especially in patients with hypercoagulability. In patients undergoing Hip and Knee Replacement, one of the standard therapies for treating DVT is by administering combination therapy (Unfractionated Heparin + Warfarin). Rivaroxaban is another therapy for the treatment of DVT which is a new oral anticoagulant (NOAC), which was developed to address the limitations of previous standard therapy, but has a more expensive price per unit. Pharmacoeconomic studies are carried out to determine the cost-effectiveness of patient treatment, one of which is carried out Cost Effectiveness Analysis (CEA), used in making decisions about selecting the best alternative in selecting medical costs. This study aims to analyze the most effective anticoagulant prophylaxis in post-treatment patients Hip and Knee Replacement at Dr. Regional General Hospital. Moewardi Surakarta. Observational descriptive research with retrospective data collection and using the CEA method. The data taken is in the form of medical records of patients undergoing procedures Total Hip and Knee Replacement with prophylactic therapy with anticoagulants. Samples were taken from 50 patients who met the inclusion and exclusion criteria. The research results showed that the ACER value of patients who used rivaroxaban prophylaxis cost Rp 24.569/day and patients who use LMWH prophylaxis incur a cost of Rp 36.304/day, so it can be concluded that the use of the drug rivaroxaban is more cost effective at RSUD Dr. Moewardi Surakarta.

References

Allen, K. D., Thoma, L. M., & Golightly, Y. M. (2022). Epidemiology of osteoarthritis. Osteoarthritis and Cartilage, 30(2), 184–195. https://doi.org/10.1016/j.joca.2021.04.020 DOI: https://doi.org/10.1016/j.joca.2021.04.020

Anderson, D. R., Dunbar, M., Murnaghan, J., Kahn, S. R., Gross, P., Forsythe, M., Pelet, S., Fisher, W., Belzile, E., Dolan, S., Crowther, M., Bohm, E., MacDonald, S. J., Gofton, W., Kim, P., Zukor, D., Pleasance, S., Andreou, P., Doucette, S., … Vendittoli, P.-A. (2018). Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty. The New England Journal of Medicine, 378(8), 699–707. https://doi.org/10.1056/NEJMoa1712746 DOI: https://doi.org/10.1056/NEJMoa1712746

Bala, A., Huddleston, J. I. 3rd, Goodman, S. B., Maloney, W. J., & Amanatullah, D. F. (2017). Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors? Clinical Orthopaedics and Related Research, 475(9), 2205–2213. https://doi.org/10.1007/s11999-017-5394-6 DOI: https://doi.org/10.1007/s11999-017-5394-6

Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001). Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet (London, England), 358(9275), 9–15. https://doi.org/10.1016/S0140-6736(00)05249-1 DOI: https://doi.org/10.1016/S0140-6736(00)05249-1

Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. J. (2012). Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141(2 Suppl), e278S-e325S. https://doi.org/10.1378/chest.11-2404 DOI: https://doi.org/10.1378/chest.11-2404

Farida, Y., Trisna, A., & Nur, D. (2017). Study of Antibiotic Use on Pneumonia Patient in Surakarta Referral Hospital. JPSCR : Journal of Pharmaceutical Science and Clinical Research, 2(01), 44. https://doi.org/10.20961/jpscr.v2i01.5240 DOI: https://doi.org/10.20961/jpscr.v2i01.5240

Heidari, B. (2011). Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian Journal of Internal Medicine, 2(2), 205–212.

Parvizi, J., Ceylan, H. H., Kucukdurmaz, F., Merli, G., Tuncay, I., & Beverland, D. (2017). Venous Thromboembolism Following Hip and Knee Arthroplasty: The Role of Aspirin. The Journal of Bone and Joint Surgery. American Volume, 99(11), 961–972. https://doi.org/10.2106/JBJS.16.01253 DOI: https://doi.org/10.2106/JBJS.16.01253

Plotnikoff, R., Karunamuni, N., Lytvyak, E., Penfold, C., Schopflocher, D., Imayama, I., Johnson, S. T., & Raine, K. (2015). Osteoarthritis prevalence and modifiable factors: a population study. BMC Public Health, 15, 1195. https://doi.org/10.1186/s12889-015-2529-0 DOI: https://doi.org/10.1186/s12889-015-2529-0

Scott, D., Brenner, B., Buller, H. R., Gallus, A. S., Anthonie, W., Misselwitz, F., Prins, M. H., Raskob, G. E., Segers, A., Wells, P., Bounameaux, H., Cohen, A., Bruce, L., Piovella, F., & Schellong, S. (2010). Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 363(26), 2499–2510. https://doi.org/10.1056/nejmoa1007903 DOI: https://doi.org/10.1056/NEJMoa1007903

Smith, S. R., Katz, J. N., & Losina, E. (2019). Cost-Effectiveness of Alternative Anticoagulation Strategies for Postoperative Management of Total Knee Arthroplasty Patients. Arthritis Care & Research, 71(12), 1621–1629. https://doi.org/10.1002/acr.23803 DOI: https://doi.org/10.1002/acr.23803

Tufanaru, C., Munn, Z., Stephenson, M., & Aromataris, E. (2015). Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. International Journal of Evidence-Based Healthcare, 13(3), 196–207. https://doi.org/10.1097/XEB.0000000000000065 DOI: https://doi.org/10.1097/XEB.0000000000000065

Ummah, M. S. (2019). No 主観的健康感を中心とした在宅高齢者における健康関連指標に関する共分散構造分析Title. In Sustainability (Switzerland) (Vol. 11, Issue 1). http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SISTEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI